UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
NEW HAVEN, Conn., March 08, 2018 -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., Chief Executive Officer of Achillion, will present a corporate overview at the Barclays Global Healthcare Conference on Thursday, March 15, 2018, at 11:15 a.m. ET at the Loews Miami Beach Hotel in Miami, FL.
The live audio and subsequent archived webcasts of the Company's presentations will be accessible from the Company's investor relations website, http://ir.achillion.com. The audio recording will be archived for 30 days following the live presentation. Please connect to Achillion's website several minutes prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is a science-driven, patient-focused company seeking to leverage its capabilities across the continuum from discovery to commercialization in its goal of providing better treatments for people with serious diseases. The company employs a highly-disciplined discovery and development approach that has allowed it to build a platform of potent and specific complement factor D inhibitors for AP-mediated diseases. Achillion is rapidly advancing its efforts to bring life-saving medicines to patients with rare diseases. More information is available at http://www.achillion.com.
Investors & Media: Glenn Schulman, PharmD, MPH Achillion Pharmaceuticals, Inc. Tel. (203) 752-5510 [email protected]
